Pattern of disease and response to pembrolizumab in recurrent cervical cancer

OBJECTIVE: Since the approval of pembrolizumab for advanced or recurrent PD-L1 positive (CPS > 1%) cervical cancer, the clinical characteristics associated with response have remained undefined. We sought to characterize the clinicopathologic features of patients with advanced cervical cancer at...

Descripción completa

Detalles Bibliográficos
Autores principales: Miller, Kathryn M., Filippova, Olga T., Hayes, Sara A., Abu-Rustum, Nadeem R., Aghajanian, Carol, Broach, Vance, Ellenson, Lora H., Selenica, Pier, Jewell, Elizabeth L., Kyi, Chrisann, Lakhman, Yuliya, Mueller, Jennifer J., O'Cearbhaill, Roisin E., Park, Kay J., Sonoda, Yukio, Zamarin, Dmitriy, Weigelt, Britta, Leitao, Mario M., Friedman, Claire F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Research Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8319446/
https://www.ncbi.nlm.nih.gov/pubmed/34345644
http://dx.doi.org/10.1016/j.gore.2021.100831

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8319446/
https://www.ncbi.nlm.nih.gov/pubmed/34345644
http://dx.doi.org/10.1016/j.gore.2021.100831

Ejemplares similares